XLO - Xilio Therapeutics, Inc.

8.57
0.220   2.567%

Share volume: 39,785
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$8.35
0.22
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 35%
Dept financing 40%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.30%
1 Month
12.76%
3 Months
1,269.01%
6 Months
1,037.06%
1 Year
951.53%
2 Year
569.53%
Key data
Stock price
$8.57
P/E Ratio 
N/A
DAY RANGE
$8.31 - $8.76
EPS 
-$0.90
52 WEEK RANGE
$0.46 - $9.25
52 WEEK CHANGE
$951.53
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
5.783 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
-1.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$28,375
AVERAGE 30 VOLUME 
$40,144
Company detail
CEO: René Russo
Region: US
Website: xiliotx.com
Employees: 70
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Xilio Therapeutics, Inc. develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate.

Recent news